Sort
21,453 grants matching “tuberculosis”
Commercial Development of the Bronx Box
$802,717Sequella, Inc. · R44 · FY2002 · AI
De facto monotherapy during multidrug TB treatment and emergence of resistance
$802,715Veronique Dartois · Rbhs-New Jersey Medical School · R01 · FY2014 · AI
Predicting tuberculosis outcomes using genotypic and biomarker signatures
$802,668Gillian L Beamer · Texas Biomedical Research Institute · R01 · FY2023 · HL
Structural Genomics of Persistence Targets from M. tuberculosis
$802,602James C Sacchettini · Texas A&M Agrilife Research · P01 · FY2010 · AI
Integrating genomic architecture and tuberculosis (TB) immunity in Africa
$802,499Paul John Norman · University Of Colorado Denver · R01 · FY2025 · AI
Analysis of Chemical Structures and Therapeutic Activity of Agents for HIV, TB, and HBV (CHEMDB)
$802,459Louise Sumner · Gryphon Scientific, Llc · N01 · FY2022 · AI
Mouse models for paucibacillary persistence
$802,328Sabine Ehrt · Weill Medical Coll Of Cornell Univ · U19 · FY2020 · AI
Immunotherapy to prevent drug-resistant tuberculosis
$802,216Rhea N Coler · Access To Advanced Health Institute · R01 · FY2019 · AI
The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis
$802,099Chetan Seshadri · University Of Washington · R01 · FY2024 · AI
Safe Pregnancy by Infectious Disease Control in Kinshasa
$802,082Carl Bose · Univ Of North Carolina Chapel Hill · U01 · FY2007 · HD
The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis
$801,468Chetan Seshadri · University Of Washington · R01 · FY2021 · AI
Foam cells as drug targets in tuberculosis
$801,457Maria Laura Gennaro · Rbhs-New Jersey Medical School · R01 · FY2019 · HL
Novel TB Prevention Regimens for HIV-Infected Adults
$801,305Johns Hopkins University · R01 · FY2005 · AI
Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage
$800,726Max O'Donnell · Columbia University Health Sciences · R01 · FY2023 · AI
A Multidisciplinary Approach to Understanding TB Latency and Reactivation
$800,674Petros C Karakousis · Johns Hopkins University · R01 · FY2010 · HL
A New Approach to an Old Problem: Redesigning Latent Tuberculosis Screening and Treatment
$800,637Sara Tartof · Kaiser Foundation Research Institute · R01 · FY2020 · AI
A Multi-scale systems pharmacology approach to TB therapy
$800,540Denise E Kirschner · University Of Michigan At Ann Arbor · U01 · FY2016 · HL
Longtitudinal Studies of HIV-Associated Bacterial Pneumonia
$800,502William N Rom · New York University School Of Medicine · R01 · FY2009 · HL
Task 6: Technical Support for Tuberculosis Therapeutics
$800,493Jon Carl Mirsalis · Sri International · N01 · FY2014 · AI
Dual Targeting of Mtb Resistance Mechanisms
$800,468Christoph Grundner · Seattle Children'S Hospital · R01 · FY2022 · AI
Human Genetic determinants of HBV recovery
$800,431David L Thomas · Johns Hopkins University · R01 · FY2021 · AI
Mechanisms of IFNg-independent T cell and B cell-mediated protection in TB.
$800,200Padmini Salgame · Rutgers Biomedical And Health Sciences · R01 · FY2024 · AI
Novel Methods to Inform HIV/TB Clinical Trial Development
$800,161Rochelle P Walensky · Massachusetts General Hospital · R37 · FY2015 · AI
The Bring BPaL2Me Trial - Comparing Nurse-Led RR-TB Treatment in Primary Care to Physician-Led, Hospital-Based RR-TB Treatment: A Cluster Randomized, Non-Inferiority Trial
$800,112Jason Edward Farley · Johns Hopkins University · R01 · FY2023 · AI
ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSIS
$800,095Shabaana A. Khader · Washington University · R01 · FY2019 · AI